Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-02-26, Stock:ABBV, The news for the past five days is as follows:
2021-02-19: NEWS1: EOLS Stock: The Big News That Has Evolus Shares Skyrocketing Today.NEWS2: Evolus Shares Surge After Settling Jeuveau Related Litigation With AbbVie, Medytox.NEWS3: AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation.NEWS4: AbbVie to Present at the Cowen 41st Annual Health Care Conference.
2021-02-22: NEWS1: Jim Simons' Firm's Top Trades of the 4th Quarter.NEWS2: AbbVie's Upadacitinib Shows Clinical Benefit In Second Late-Stage Ulcerative Colitis Study.NEWS3: Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients.NEWS4: 3 Stocks to Buy with Dividends Yielding More than 4%.
2021-02-23: NEWS1: New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use.NEWS2: 2 Best Pharma Stocks to Buy Right Now.NEWS3: Warren Buffett Just Bought These 2 Dirt-Cheap Stocks. Should You?.
2021-02-24: NEWS1: AbbVie's SKYRIZI® for the Treatment of Moderate to Severe Plaque Psoriasis now Publicly Reimbursed across Canada.NEWS2: Top 15 Pharmaceutical Companies With Highest R&D Spending.
2021-02-25: NEWS1: The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants.NEWS2: Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia.NEWS3: HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis.

Answer: Rise